Photodynamic therapy of idiopathic and inflammatory choroidal neovascularization in young adults

Rogers, Adam H.; Duker, Jay S.; Nichols, Neil; Baker, Brad J.

doi:10.1016/s0161-6420(03)00466-4

Cited by 66 publications

(42 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The group of younger patients in our study experienced an early and noticeable change in VA from a mean logMAR of 0.46 at 1-month follow-up to a mean logMAR of 0.31 at 3-month follow-up. This trend indicates a more rapid effect of treatment in younger patients, similar to that observed by Rogers et al 23 in their case series of 19 eyes with subfoveal idiopathic and inflammatory CNV.…”

Section: Discussionsupporting

confidence: 85%

Photodynamic therapy of idiopathic subfoveal choroidal neovascularization in Taiwanese patients: a 2-year follow-up

Lin

Tseng

et al. 2008

Eye

View full text Add to dashboard Cite

Aims: To study the efficacy of verteporfin photodynamic therapy (VPDT) retrospectively in the treatment of idiopathic subfoveal choroidal neovascularization (ICNV) in an Asian population in correlation with number of treatments and age at treatment. This is the first report to compare the efficacy between single and multiple treatments. Results: The 28 patients receiving a single VPDT treatment showed significant improvement in VA at 3-month follow-up. The 17 patients, who did not show improvement after the first treatment, received multiple VPDT treatments. Those patients showed an even clearer trend in VA improvement although significance was detected only at the 24th month. All patients showed a significant improvement in mean VA of 0.46 logMAR (Po0.01 compared to baseline) by the end of the 24-month observation period, although VPDT treatment for subfoveal ICNV appears to stabilize vision more rapidly in younger patients. Conclusions: ICNV patients who did not benefit from single VPDT treatments could receive multiple treatments, and showed a more significant improvement in visual acuity. These results are the first of their kind in ICNV treatment.

show abstract

Section: Discussionsupporting

confidence: 85%

Photodynamic therapy of idiopathic subfoveal choroidal neovascularization in Taiwanese patients: a 2-year follow-up

Lin

Tseng

et al. 2008

Eye

View full text Add to dashboard Cite

show abstract

“…Subfoveal choroidal neovascular degeneration (CNV) is another area of significant interest for PDT [152]. CNV can occur as a complication of inflammatory conditions [153] and a combination of verteporfin PDT and immunosuppression has shown promise for inflammatory subfoeval CNV [154][155][156][157][158]. Photodynamic therapy with verteporfin is currently the only photosensitizer that is approved by regulatory agencies for the treatment of CNV secondary to pathologic myopatia and has shown beneficial effects [159].…”

Section: Current Developmentsmentioning

confidence: 99%

Nanodrug applications in photodynamic therapy

Paszko

Ehrhardt

Senge

et al. 2011

Photodiagnosis and Photodynamic Therapy

326

215

View full text Add to dashboard Cite

SummaryPhotodynamic therapy (PDT) has developed over last century and is now becoming a more widely used medical tool having gained regulatory approval for the treatment of various diseases such as cancer and macular degeneration. It is a two-step technique in which delivery of a photosensitizing drug is followed by irradiation of light. Activated photosensitizers transfer energy to molecular oxygen which results in generation of reactive oxygen species which in turn cause cells apoptosis or necrosis. Although this modality has significantly improved quality of life and survival time for many cancer patients it still offers significant potential for further improvement. In addition to the development of new PDT drugs, the use of nanosized carriers for photosensitizers is a promising approach which might improve the efficiency of photodynamic activity and which can overcome many side effects associated with classic photodynamic therapy. This review aims at highlighting the different types of nanomedical approaches currently used in PDT and outlines future trends and limitations of nanodelivery of photosensitizers. PDT -photodynamic therapy; PGA -poly(glycolic acid); PGLA -poly(D,L-lactide-coglycolide); PLA -poly(lactic acid); PS -photosensitizer; PEG -polyethylene glycol; ALA  aminolevulinic acid; m-THPC  5,10,15,20-tetra-(m-hydroxyphenyl)chlorine; m-THPP  meso-tetra(p-hydroxyphenyl); PpIX  protoporphyrin; Hp  hematoporphyrin; Pc4  silicon phthalocyanine; Ig  immunoglobulin; Tf  transferrin; TfR  transferrin receptor; VEGF  vascular endothelial growth factor; EPR  enhanced permeability and retention effect; FRET  fluorescence resonance energy transfer; MRI  magnetic resonance imaging; RES  reticuloendothelial system; ROS  reactive oxygen species; NP  nanoparticle; ND -nanodiamonds; SNP  silica nanoparticle; AMD  age-related macular degeneration; CNV  choroidal neovascularization; PTT  photothermal therapy;

show abstract

“…Stabilised or improved vision occurred in 70-92.3% of cases reported in retrospective studies. 67,68 One study reported on 13 multifocal choroiditis with panuveitis and subfoveal CNV patients who received PDT and reported stabilisation of vision over a 12-month follow-up. 62 A prospective study after a combination of intravitreal triamcinolone and PDT therapy reported stabilised or improved vision in 92.9% of patients at the end of 1 year.…”

Section: Anti-inflammatory and Immunosuppressive Agentsmentioning

confidence: 99%

Intravitreal bevacizumab for choroidal neovascularisation secondary to causes other than age-related macular degeneration

Gupta

Elagouz

Sivaprasad

2009

Eye

View full text Add to dashboard Cite

Choroidal neovascularisation (CNV) is characterised by new blood vessel growth under the retina that usually results in significant visual impairment when the fovea is involved. Though CNV is more commonly associated with age-related macular degeneration (AMD), it can occur secondary to a variety of other diseases. Recent successes with anti-angiogenic therapies suggest that they may outperform other therapies for all types of CNV. As non-AMD-related CNV cases are rare, randomised controlled trials are often not possible. This review compares the less prevalent reports of non-AMD CNV and pools evidence on the success and limitations of a variety of therapies.

show abstract

Photodynamic therapy of idiopathic and inflammatory choroidal neovascularization in young adults

Cited by 66 publications

References 13 publications

Photodynamic therapy of idiopathic subfoveal choroidal neovascularization in Taiwanese patients: a 2-year follow-up

Photodynamic therapy of idiopathic subfoveal choroidal neovascularization in Taiwanese patients: a 2-year follow-up

Nanodrug applications in photodynamic therapy

Intravitreal bevacizumab for choroidal neovascularisation secondary to causes other than age-related macular degeneration

Contact Info

Product

Resources

About